Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
Scleroderma, the physical and emotional impact
Article by doctor Susana Oliveira, graduated Hospital Assistant and Systemic Sclerosis Consulting Coordinator at the Professor Doutor Fernando Fonseca Hospital
Schutz vor Covid-19-jetzt nicht nachlassen
Artikel von Maria José Guimarães, Pulmonologin, Koordinatorin des pneumologischen Dienstes des Krankenhauses von Luz-Guimarães.
Do not make it easy!
Opinion article by Dr. Maria José Guimarães, Pulmonologist, Coordinator of the Pneumology Service of the Luz-Guimarães Hospital